Bifogade filer
Toleranzia takes part in a research consortium that has been granted support from the Swedish Knowledge Foundation
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Swedish Knowledge Foundation, KKS, has approved an application within the Synergy programme for a research collaboration where Toleranzia will participate as an industry partner. The research project will focus on drug discovery targeting inflammation and is granted 10 MSEK in support from KKS.
The approved project application, entitled “Drug discovery targeting inflammation – novel therapeutic aspects on vascular inflammation, thrombosis and breast cancer”, will be coordinated by the Cardiovascular Research Centre (CVRC) at Örebro University.
Within the project, CVRC will support Toleranzia´s drug development activities by investigating basic mechanisms of vascular inflammation in the Company’s models of autoimmunity, as well as the effect of therapeutic intervention on markers of inflammation.
“We are very pleased to be part of this research consortium which will generate new insights into inflammatory processes in autoimmunity and in which we will contribute with our knowledge of developing tolerogenic therapies. Although Toleranzia is not a recipient of direct funding, the project is of great value to us as we get access to external expertise and resources to further investigate the in vivo effects of our drug candidates”, comments Charlotte Fribert, CEO of Toleranzia.
For further information, please contact:
Charlotte Fribert - CEO, Toleranzia
Tel: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the Company's Certified Adviser.